Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × azeliragon × Clear all

Phase

Phase 1/2 4 Phase 1 2 Phase EARLY_PHASE1 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 1267 Carboplatin 1173 Cyclophosphamide 1128 Gemcitabine 1030 Bevacizumab 1011 Paclitaxel 1005 Radiotherapy 995 Docetaxel 930 pembrolizumab 864 Oxaliplatin 777 Capecitabine 758 Fluorouracil 717 Rituximab 621 Doxorubicin 563 Dexamethasone 560 Nivolumab 555 Etoposide 555 Irinotecan 534 Leucovorin 493 Pemetrexed 423 Drug Therapy 403 Cetuximab 398 Cytarabine 396 Trastuzumab 391 Filgrastim 373 Magnetic Resonance Spectroscopy 365 Prednisone 357 Lenalidomide 342 Bortezomib 339 Temozolomide 331

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05986851 2024-09-05

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡